Company intelligence / Profile preview

Vivid Frontier

Nanjing, Jiangsu Province, Chinafacebook.com ↗

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Frontier Biotechnologies has successfully commercialized Aikening™ (Albuvirtide), the first long-acting injectable HIV fusion inhibitor in the world, with marketing authorization in China since May 2018 and additional approvals in several emerging markets. The company maintains a diversified R&D pipeline with ongoing clinical trials targeting antiviral diseases (HIV, COVID-19, HBV), osteoporosis, pain management, and hyperlipidemia. Manufacturing facilities are certified to international standards including US FDA cGMP[1][2][5].

Therapeutic areas: CardiovascularEndocrinologyInfectious DiseasesNeurology
Modalities: PeptidesSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Vivid Frontier.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivid Frontier.

Explore the full profile